353 related articles for article (PubMed ID: 25832325)
21. Pilot Experience Using Drug Provocation Testing for the Study of Hypersensitivity to Chemotherapy and Biological Agents.
Martí-Garrido J; Vázquez-Revuelta P; Lleonart-Bellfill R; Molina-Mata K; Muñoz-Sánchez C; Madrigal-Burgaleta R
J Investig Allergol Clin Immunol; 2021 Apr; 31(2):166-168. PubMed ID: 32573462
[No Abstract] [Full Text] [Related]
22. Nanoallergen platform for detection of platin drug allergies.
Deak PE; Kim B; Adnan A; Labella M; De Las Vecillas L; Castells M; Bilgicer B
J Allergy Clin Immunol; 2019 May; 143(5):1957-1960.e12. PubMed ID: 30682456
[TBL] [Abstract][Full Text] [Related]
23. Impact of an extended challenge on the effectiveness of β-lactam hypersensitivity investigation.
Ratzon R; Reshef A; Efrati O; Deutch M; Forschmidt R; Cukierman-Yaffe T; Kenett R; Kidon MI
Ann Allergy Asthma Immunol; 2016 Apr; 116(4):329-33. PubMed ID: 26922211
[TBL] [Abstract][Full Text] [Related]
24. Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin.
Pagani M; Bonadonna P; Senna GE; Antico A
Int Arch Allergy Immunol; 2008; 145(1):54-7. PubMed ID: 17703101
[TBL] [Abstract][Full Text] [Related]
25. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol.
Gammon D; Bhargava P; McCormick MJ
Oncologist; 2004; 9(5):546-9. PubMed ID: 15477639
[TBL] [Abstract][Full Text] [Related]
26. Opioid Hypersensitivity: Predictors of Allergy and Role of Drug Provocation Testing.
Li PH; Ue KL; Wagner A; Rutkowski R; Rutkowski K
J Allergy Clin Immunol Pract; 2017; 5(6):1601-1606. PubMed ID: 28550985
[TBL] [Abstract][Full Text] [Related]
27. Endophenotyping Oxaliplatin Hypersensitivity: Personalizing Desensitization to the Atypical Platin.
Silver J; Garcia-Neuer M; Lynch DM; Pasaoglu G; Sloane DE; Castells M
J Allergy Clin Immunol Pract; 2020 May; 8(5):1668-1680.e2. PubMed ID: 32112926
[TBL] [Abstract][Full Text] [Related]
28. Oxaliplatin hypersensitivity: case report and successful repeat desensitization.
Edmondson DA; Gruling BJ; Urmanski AM; Wong SJ; Levy MB
Am J Ther; 2007; 14(1):116-8. PubMed ID: 17303980
[TBL] [Abstract][Full Text] [Related]
29. Short and extended provocation tests have similar negative predictive value in non-immediate hypersensitivity to beta-lactams in children.
Regateiro FS; Rezende I; Pinto N; Abreu C; Carreiro-Martins P; Gomes ER
Allergol Immunopathol (Madr); 2019; 47(5):477-483. PubMed ID: 30910271
[TBL] [Abstract][Full Text] [Related]
30. Drug provocation tests in hypersensitivity drug reactions.
Rerkpattanapipat T; Chiriac AM; Demoly P
Curr Opin Allergy Clin Immunol; 2011 Aug; 11(4):299-304. PubMed ID: 21659856
[TBL] [Abstract][Full Text] [Related]
31. Rapid desensitization of hypersensitivity reactions to chemotherapy agents.
Castells M
Curr Drug Saf; 2006 Aug; 1(3):243-51. PubMed ID: 18690934
[TBL] [Abstract][Full Text] [Related]
32. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
Hesterberg PE; Banerji A; Oren E; Penson RT; Krasner CN; Seiden MV; Wong JT
J Allergy Clin Immunol; 2009 Jun; 123(6):1262-7.e1. PubMed ID: 19501233
[TBL] [Abstract][Full Text] [Related]
33. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule.
Meyer L; Zuberbier T; Worm M; Oettle H; Riess H
J Clin Oncol; 2002 Feb; 20(4):1146-7. PubMed ID: 11844841
[No Abstract] [Full Text] [Related]
34. Hypersensitivity reactions associated with oxaliplatin and their clinical management.
Toki MI; Saif MW; Syrigos KN
Expert Opin Drug Saf; 2014 Nov; 13(11):1545-54. PubMed ID: 25307143
[TBL] [Abstract][Full Text] [Related]
35. Successful desensitization to oxaliplatin.
Mis L; Fernando NH; Hurwitz HI; Morse MA
Ann Pharmacother; 2005 May; 39(5):966-9. PubMed ID: 15784807
[TBL] [Abstract][Full Text] [Related]
36. Patients' satisfaction with diagnostic drug provocation tests and perception of its usefulness.
Gomes ER; Kvedariene V; Demoly P; Bousquet PJ
Int Arch Allergy Immunol; 2011; 156(3):333-8. PubMed ID: 21720180
[TBL] [Abstract][Full Text] [Related]
37. Hypersensitivity and idiosyncratic reactions to oxaliplatin.
Bhargava P; Gammon D; McCormick MJ
Cancer; 2004 Jan; 100(1):211-2. PubMed ID: 14692042
[No Abstract] [Full Text] [Related]
38. Desensitization with oxaliplatin in patients intolerant of carboplatin desensitization.
Rose PG; Metz C; Link N
Int J Gynecol Cancer; 2014 Nov; 24(9):1603-6. PubMed ID: 25304679
[TBL] [Abstract][Full Text] [Related]
39. Anaphylaxis to chemotherapy and monoclonal antibodies.
Castells MC
Immunol Allergy Clin North Am; 2015 May; 35(2):335-48. PubMed ID: 25841555
[TBL] [Abstract][Full Text] [Related]
40. Outcome of 490 Desensitizations to Chemotherapy Drugs with a Rapid One-Solution Protocol.
Pérez-Rodríguez E; Martínez-Tadeo JA; Pérez-Rodríguez N; Hernández-Santana G; Callero-Viera A; Rodríguez-Plata E; García-Robaina JC
J Allergy Clin Immunol Pract; 2018; 6(5):1621-1627.e6. PubMed ID: 29361511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
